Monitor upcoming clinical data readouts in June (ITP) and Q4 2026 (pMN, SLE) as key catalysts. The SC formulation data is positive but early; the stock may trade on binary trial outcomes rather than this routine disclosure.
Price Chart
Executive Summary
Climb Bio hosted an R&D Spotlight event on May 5, 2026, presenting positive topline data for its subcutaneous budoprutug formulation in healthy volunteers (showing ~80% B-cell depletion with similar magnitude to IV) and reiterating upcoming clinical milestones across pMN, ITP, and SLE programs. The filing is a routine Regulation FD disclosure of an investor presentation and press release; no new financial data or material definitive agreements were reported.
Key Facts
- Budoprutug SC demonstrated ~80% B-cell depletion in healthy volunteers, similar to IV at matched doses
- ITP Phase 1b/2a initial B-cell and platelet data from low-dose cohort (250 mg) expected June 2026
- pMN Phase 2 initial B-cell and anti-PLA2R data from low-dose cohort (200 mg) expected Q4 2026
- SLE Phase 1b global study initial B-cell data expected Q4 2026
- China SLE Phase 1b first patient in expected Q2 2026
- Budoprutug has Fast Track and Orphan Drug Designations for pMN
- Cash runway anticipated into 2028, excluding April PIPE proceeds
Financial Impact
No financial figures reported; clinical-stage biotech with no revenue or earnings data in filing
Risk Factors
- Clinical trial failure or disappointing efficacy/safety data in upcoming readouts
- Need for substantial additional capital to fund development beyond 2028
- Competitive landscape includes multiple CD19-targeting modalities (CAR-T, TCEs) and established anti-CD20 therapies
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-205079 |
| Document: d127757d8k.htm | 0001193125-26-205079 |
| Document: d127757dex991.htm | 0001193125-26-205079 |
| Document: 0001193125-26-205079-index-headers.html | 0001193125-26-205079 |
| Document: 0001193125-26-205079-index.html | 0001193125-26-205079 |
| Document: 0001193125-26-205079.txt | 0001193125-26-205079 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | 8-K | $10.92 | awaiting T+1 | — | $9.59 (−12.23%) |
Oct 23, 2026 3d ago | 8-K | $10.47 | awaiting T+1 | — | $9.59 (−8.45%) |
Oct 23, 2026 4d ago | Press Release | $10.34 | awaiting T+1 | — | $9.59 (−7.30%) |
Sep 22, 2026 5w ago | Institutional Cluster | $14.21 $12.52 | ▼ −11.89% | ▼ −11.17% | $9.59 (−32.55%) |
Sep 3, 2026 7w ago | 8-K | $14.59 $15.52 | ▲ +6.37% | ▲ +6.76% | $9.59 (−34.30%) |
Aug 14, 2026 10w ago | 8-K | $16.33 $17.44 | ▲ +6.80% | ▲ +7.27% | $9.59 (−41.30%) |
Aug 6, 2026 11w ago | 8-K | $14.00 $14.00 | · 0.00% | ▼ −0.61% | $9.59 (−31.54%) |
Jun 30, 2026 16w ago | 144 | $13.29 $12.90 | ▼ −2.93% | ▼ −2.80% | $9.59 (−27.88%) |
Jun 12, 2026 19w ago | 8-K | $11.49 $10.71 | ▲ +6.79% | ▲ +6.19% | $9.59 (+16.58%) |
Jun 12, 2026 19w ago | 424B5 | $11.49 $10.71 | ▲ +6.79% | ▲ +6.19% | $9.59 (+16.58%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers